IDIA.SW Idorsia Ltd (SIX) down 9.00% to CHF3.54 on 12 Mar 2026: analyst focus

IDIA.SW stock led today’s losers on the SIX, sliding 9.00% to CHF 3.54 at the close on 12 Mar 2026. Volume finished at 2.10M shares, above the 50-day average, signalling heavier selling interest. The drop widened YTD underperformance to -12.93% versus the Swiss healthcare sector’s -3.59% YTD. Traders cited mixed fundamentals, an upcoming earnings date and technical weakness as immediate pressure points for Idorsia Ltd on the Switzerland exchange.

IDIA.SW stock price action and session data

Idorsia Ltd (IDIA.SW) opened at CHF 3.90 and traded between CHF 3.54 and CHF 3.94 before closing at CHF 3.54 on SIX. Daily volume was 2.10M vs average 1.49M, giving a relative volume of 1.40, which confirms the stock was a top loser by activity. Year range remains CHF 0.85 to CHF 4.85, and the 50-day and 200-day averages sit at CHF 3.77 and CHF 3.34 respectively.

What moved IDIA.SW stock today: drivers and catalysts

Selling ramped up ahead of Idorsia’s next scheduled earnings announcement on 28 Apr 2026, which traders flagged as a near-term catalyst. Market participants pointed to persistent negative EPS of -0.52 and a negative PE of -6.80 as reasons for caution. Idorsia’s partnerships and pipeline are positives but did not offset short-term selling pressure during the session.

IDIA.SW stock fundamentals and valuation

Idorsia reports a market cap near CHF 705.52M and enterprise value about CHF 1.96B, reflecting debt and capital structure in the biotech model. Key ratios show negative free cash flow per share -0.70 and book value per share -4.58, while the current ratio is 1.39, indicating modest short-term liquidity. The company spends 32.94% of revenue on R&D (ratio shown as 0.329), consistent with biotech peers but weighing on near-term profitability.

IDIA.SW stock technicals and trading signals

Technical indicators are neutral to weak for IDIA.SW: RSI 51.97 shows no extreme, MACD is flat and ADX 15.57 indicates no clear trend. Bollinger Bands middle sits at CHF 3.85 and lower at CHF 3.51, placing the close near the band base. The on-balance volume is negative, matching the larger-than-average sell volume and signalling distribution.

Meyka AI rates IDIA.SW with a score out of 100 and model forecasts

Meyka AI rates IDIA.SW with a score out of 100: 72.24 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, industry benchmarks, financial growth, key metrics, forecasts, analyst consensus and fundamental growth. Note other models show a weaker company rating (C- / Strong Sell) reflecting short-term financial stress and valuation dispersion. Meyka AI’s forecast model projects a monthly value of CHF 3.53, a 1-year target of CHF 5.60 and a 3-year target of CHF 9.90; the 1-year model implies an upside of 58.12% versus today’s CHF 3.54. Forecasts are model-based projections and not guarantees.

Risks and near-term opportunities for IDIA.SW stock

Idorsia faces execution risk tied to trial readouts and commercialisation of partnered assets, which can swing biotech valuations rapidly. Liquidity is reasonable with 2.10M shares traded, but negative cash flow per share and a negative PE create downside if pipeline milestones slip. Conversely, successful trial updates or positive earnings on 28 Apr 2026 could trigger a rapid re-rating given the stock’s low float and partnerships with larger pharma players.

Final Thoughts

IDIA.SW stock closed the session on 12 Mar 2026 down 9.00% at CHF 3.54, marking it among the top losers on SIX for the day. Short-term pressure is driven by mixed fundamentals, negative EPS -0.52, and an approaching earnings announcement on 28 Apr 2026. Meyka AI’s model offers a 1-year projection of CHF 5.60, implying a potential upside of 58.12%, while the 3-year projection reaches CHF 9.90. Traders should weigh the model upside against present cash-flow and valuation risks. For context, the Swiss healthcare sector is less weak YTD at -3.59%, highlighting Idorsia’s relative underperformance. Use the next earnings update and trial milestones as decision points; monitor volume and RSI for confirmation before entering positions. Meyka AI provides this as an AI-powered market analysis platform insight; forecasts are model-based and not investment guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.